These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 9751625

  • 1. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
    Koppan M, Nagy A, Schally AV, Arencibia JM, Plonowski A, Halmos G.
    Cancer Res; 1998 Sep 15; 58(18):4132-7. PubMed ID: 9751625
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K.
    Cancer Res; 1999 Apr 15; 59(8):1947-53. PubMed ID: 10213505
    [Abstract] [Full Text] [Related]

  • 3. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J, Reile H, Halmos G, Groot K, Schally AV.
    Cancer Res; 1994 Jan 01; 54(1):169-74. PubMed ID: 7903203
    [Abstract] [Full Text] [Related]

  • 4. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
    Kiaris H, Schally AV, Nagy A, Sun B, Szepeshazi K, Halmos G.
    Clin Cancer Res; 2000 Feb 01; 6(2):709-17. PubMed ID: 10690557
    [Abstract] [Full Text] [Related]

  • 5. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
    Plonowski A, Schally AV, Nagy A, Sun B, Halmos G.
    Int J Oncol; 2002 Feb 01; 20(2):397-402. PubMed ID: 11788908
    [Abstract] [Full Text] [Related]

  • 6. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
    Szepeshazi K, Schally AV, Halmos G, Sun B, Hebert F, Csernus B, Nagy A.
    Clin Cancer Res; 2001 Sep 01; 7(9):2854-61. PubMed ID: 11555603
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
    Plonowski A, Schally AV, Nagy A, Kiaris H, Hebert F, Halmos G.
    Cancer Res; 2000 Jun 01; 60(11):2996-3001. PubMed ID: 10850448
    [Abstract] [Full Text] [Related]

  • 8. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 9. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L, Schally AV, Nagy A, Armatis P, Szepeshazi K, Halmos G.
    Clin Cancer Res; 2000 Oct 01; 6(10):4158-65. PubMed ID: 11051271
    [Abstract] [Full Text] [Related]

  • 10. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
    Szereday Z, Schally AV, Szepeshazi K, Bajo AM, Hebert F, Halmos G, Nagy A.
    Int J Oncol; 2003 May 01; 22(5):1141-6. PubMed ID: 12684683
    [Abstract] [Full Text] [Related]

  • 11. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
    Nagy A, Schally AV, Halmos G, Armatis P, Cai RZ, Csernus V, Kovács M, Koppán M, Szepesházi K, Kahán Z.
    Proc Natl Acad Sci U S A; 1998 Feb 17; 95(4):1794-9. PubMed ID: 9465096
    [Abstract] [Full Text] [Related]

  • 13. Inhibitory effect of somatostatin analogue RC-160 on the growth of hepatic metastases of colon cancer in rats: a study with magnetic resonance imaging.
    Qin Y, Van Cauteren M, Osteaux M, Schally AV, Willems G.
    Cancer Res; 1992 Nov 01; 52(21):6025-30. PubMed ID: 1356623
    [Abstract] [Full Text] [Related]

  • 14. Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice.
    Kiaris H, Schally AV, Nagy A, Sun B, Armatis P, Szepeshazi K.
    Br J Cancer; 1999 Nov 01; 81(6):966-71. PubMed ID: 10576652
    [Abstract] [Full Text] [Related]

  • 15. Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    J Urol; 2004 Feb 01; 171(2 Pt 1):911-5. PubMed ID: 14713852
    [Abstract] [Full Text] [Related]

  • 16. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB, Keller G, Schally AV, Halmos G, Hammann B, Nagy A.
    Clin Cancer Res; 2005 Mar 15; 11(6):2408-15. PubMed ID: 15788692
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238.
    Kahán Z, Nagy A, Schally AV, Hebert F, Sun B, Groot K, Halmos G.
    Int J Cancer; 1999 Aug 12; 82(4):592-8. PubMed ID: 10404076
    [Abstract] [Full Text] [Related]

  • 18. Partial inhibition of the growth of transplanted dunning rat prostate tumors with the long-acting somatostatin analogue sandostatin (SMS 201-995).
    Siegel RA, Tolcsvai L, Rudin M.
    Cancer Res; 1988 Aug 15; 48(16):4651-5. PubMed ID: 2899458
    [Abstract] [Full Text] [Related]

  • 19. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice.
    Shen H, Hu D, Du J, Wang X, Liu Y, Wang Y, Wei JM, Ma D, Wang P, Li L.
    Eur J Pharmacol; 2008 Dec 28; 601(1-3):23-9. PubMed ID: 18983839
    [Abstract] [Full Text] [Related]

  • 20. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K, Schally AV, Treszl A, Seitz S, Halmos G.
    Anticancer Drugs; 2008 Apr 28; 19(4):349-58. PubMed ID: 18454045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.